[go: up one dir, main page]

WO2007031727A3 - System for delivering neuronal calcium sensor - 1 (ncs - 1) - Google Patents

System for delivering neuronal calcium sensor - 1 (ncs - 1) Download PDF

Info

Publication number
WO2007031727A3
WO2007031727A3 PCT/GB2006/003367 GB2006003367W WO2007031727A3 WO 2007031727 A3 WO2007031727 A3 WO 2007031727A3 GB 2006003367 W GB2006003367 W GB 2006003367W WO 2007031727 A3 WO2007031727 A3 WO 2007031727A3
Authority
WO
WIPO (PCT)
Prior art keywords
ncs
delivering
calcium sensor
neuronal calcium
neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/003367
Other languages
French (fr)
Other versions
WO2007031727A2 (en
Inventor
Liang-Fong Wong
Nicholas Mazarakis
Susan Kingsman
Ping Yip
Jonathan Corcoran
Stephen Mcmahon
Malcom Maden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Oxford Biomedica UK Ltd
Original Assignee
Kings College London
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London, Oxford Biomedica UK Ltd filed Critical Kings College London
Priority to EP06779383A priority Critical patent/EP1937820A2/en
Publication of WO2007031727A2 publication Critical patent/WO2007031727A2/en
Anticipated expiration legal-status Critical
Publication of WO2007031727A3 publication Critical patent/WO2007031727A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a system capable of delivering neuronal calcium sensor-1 (NCS-1), or a nucleotide sequence encoding NCS-1 to a target cell, for promoting neurite outgrowth. The system may be used in the manufacture of a pharmaceutical composition for the treatment of a condition such as spinal cord injury.
PCT/GB2006/003367 2005-09-13 2006-09-11 System for delivering neuronal calcium sensor - 1 (ncs - 1) Ceased WO2007031727A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06779383A EP1937820A2 (en) 2005-09-13 2006-09-11 System for delivering neuronal calcium sensor-1 (ncs-1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0518674.7 2005-09-13
GB0518674A GB0518674D0 (en) 2005-09-13 2005-09-13 System

Publications (2)

Publication Number Publication Date
WO2007031727A2 WO2007031727A2 (en) 2007-03-22
WO2007031727A3 true WO2007031727A3 (en) 2008-05-15

Family

ID=35221413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003367 Ceased WO2007031727A2 (en) 2005-09-13 2006-09-11 System for delivering neuronal calcium sensor - 1 (ncs - 1)

Country Status (3)

Country Link
EP (1) EP1937820A2 (en)
GB (1) GB0518674D0 (en)
WO (1) WO2007031727A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3432911B1 (en) * 2016-03-23 2025-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Agonists of the neuronal calcium sensor 1 for treating wolfram syndrome
CN112852976B (en) * 2021-03-17 2023-10-31 湖北省农业科学院畜牧兽医研究所 Molecular marker related to later egg laying characteristics in NCS1 gene of laying hen and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075135A1 (en) * 2000-03-30 2001-10-11 Oxford Biomedica (Uk) Limited Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders
EP1250931A1 (en) * 2001-04-17 2002-10-23 F. Hoffmann-La Roche Ag Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075135A1 (en) * 2000-03-30 2001-10-11 Oxford Biomedica (Uk) Limited Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders
EP1250931A1 (en) * 2001-04-17 2002-10-23 F. Hoffmann-La Roche Ag Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAWASAKI T, ET AL.: "SPATIOTEMPORAL DISTRIBUTION OF NEURONAL CALCIUM SENSOR-1 IN THE DEVELOPING RAT SPINAL CORD", THE JOURNAL OF COMPARATIVE NEUROLOGY, vol. 460, 2003, pages 465 - 475, XP009076437 *
NAKAMURA T Y, ET AL.: "NOVEL ROLE OF NEURONAL CA2+ SENSOR-1 AS A SURVIVAL FACTOR UP-REGULATED IN INJURED NEURONS", THE JOURNAL OF CELL BIOLOGY, vol. 172, no. 7, 27 March 2006 (2006-03-27), pages 1081 - 1091, XP002412312 *
PAN C-Y, ET AL.: "ALTERATIONS IN EXOCYTOSIS INDUCED BY NEURONAL CA2+ SENSOR-1 IN BOVINE CHROMAFFIN CELLS", THE JOURNAL OF NEUROSCIENCE, vol. 22, no. 7, 2002, pages 2427 - 2433, XP002412311 *

Also Published As

Publication number Publication date
EP1937820A2 (en) 2008-07-02
GB0518674D0 (en) 2005-10-19
WO2007031727A2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
WO2007006307A3 (en) Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
TW200612892A (en) Novel compounds
WO2006135915A3 (en) Methods and compositions for treating degenerative bone disorders
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2006128693A3 (en) 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008014311A3 (en) Inhibitors of undecaprenyl pyrophosphate synthase
WO2007120689A3 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
WO2008057933A3 (en) Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
WO2008014307A3 (en) Inhibitors of undecaprenyl pyrophosphate synthase
WO2007025709A3 (en) Organic compounds
WO2008148873A3 (en) Hydroxyproline compositions and uses thereof
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
WO2008141308A3 (en) Gene expression and pain
WO2008064202A3 (en) Modified-release formulations of calcium receptor-active compounds
TW200745003A (en) Novel compounds
TW200621690A (en) Novel compounds
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2008109165A3 (en) Mineralized guided bone regeneration membranes and methods of making the same
WO2010019511A3 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
WO2008069876A3 (en) Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2009115252A3 (en) Substituted pyrazolamides and the use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006779383

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006779383

Country of ref document: EP